1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

St. Jude's Newly Approved Axium Stimulator Could Be Market Game-Changer

St. Jude followed through on its 2015 acquisition of start-up Spinal Modulation with an FDA approval of the Axium neurostimulator for chronic intractable pain. It's the first such device to target the dorsal root ganglion and could expand the overall size of the spinal cord stimulation market.

FDA approved St. Jude Medical Inc.'s Axium neurostimulator system, which employs a novel mechanism to treat pain. The company expects the product to be an important driver of its accelerating neuromodulation business, and analysts say the device – which stimulates the dorsal root ganglion (DRG) – could increase the overall size of the spinal cord stimulation market.

Axium was approved specifically to treat moderate to severe chronic intractable pain of the lower limbs in adult patients with...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Clinical Trials

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

More from R&D

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 
• By Natasha Barrow

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By Marion Webb

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.